diisopropyl (S)-glutamate | 25975-47-7

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: diisopropyl (S)-glutamate
• 英文别名: Dipropan-2-yl L-glutamate；dipropan-2-yl (2S)-2-aminopentanedioate
• CAS: 25975-47-7
• 化学式: C₁₁H₂₁NO₄
• 分子量: 231.292
• InChiKey: MULMBFBZGGMART-VIFPVBQESA-N

物化性质

• 沸点：
  286.7±25.0 °C(Predicted)
• 密度：
  1.042±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  16
• 可旋转键数：
  8
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.82
• 拓扑面积：
  78.6
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  diisopropyl (S)-glutamate 在 氢氧化钾 、 potassium carbonate 、 溶剂黄146 、 三乙胺 、 氯甲酸甲酯 作用下， 以 1,4-二氧六环 、 甲醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 28.0h， 生成 (S)-1-(2,2-diethoxyethyl)-N-<2-(indol-3-yl)ethyl>-5-oxopyrrolidine-2-carboxamide
  参考文献：
  名称：

  对映体纯E-Nor-15-氮杂杂陈代谢物的合成

  摘要：

  据报道，通过色胺与焦谷氨酸4的衍生物缩合，立体异构地合成对映体纯的E-nor-15-氮杂杂陈代谢物。当在回流的AcOH水溶液中引发Pictet - Spengler反应时，获得了几乎等摩尔比的内酰胺7和8，而在动力学控制（TFA，室温）下，反式衍生物8是主要产物。相反，用TsOH对酰胺基缩醛12进行环化，得到了顺式-衍生物7作为主要成分。

  DOI：

  10.1002/hlca.19920750110
• 作为产物：
  描述：

  L-谷氨酸 、 异丙醇 在 硫酸 作用下， 以 甲苯 为溶剂， 反应 24.0h， 以99%的产率得到diisopropyl (S)-glutamate
  参考文献：
  名称：

  Amino acids as chiral educts for asymmetric products. Chirally specific syntheses of tylophorine and cryptopleurine

  摘要：

  DOI：

  10.1021/jo00171a014

文献信息

• Stereospecific Synthesis of 2,3-Dimethoxy-naphtho[1,2-b]indolizidine
  作者：Gwan Sun Lee、Yong Seo Cho、Sang Chul Shim、Wan Joo Kim、Ernst Eibler、Wolfgang Wiegrebe

  DOI：10.1002/ardp.19893221008

  日期：——

  (11aR)‐2,3‐dimethoxy‐naphtho[1,2‐b]indolizidine (9a and 9b) were synthesized from optically pure L‐ and D‐glutamic acid through several steps (scheme 1). All the intermediates of the route to the optical antipodes of 9 exhibit identical physical and spectral properties except the sign of the optical rotation values. The optical purity of the enantiomers of 6 was checked by 1H‐NMR spectra using Eu(tfc)3,

  (11aS) - 和 (11aR) -2,3 - 二甲氧基 - 萘并 [1,2 - b] 吲哚里西啶（9a 和 9b）由光学纯的 L- 和 D-谷氨酸通过几个步骤合成（方案 1）。除了旋光度值的符号外，通往 9 的光学对映体的路线的所有中间体都表现出相同的物理和光谱特性。6 对映异构体的光学纯度通过使用 Eu (tfc) 3 的 1H-NMR 光谱检查，9 的对映异构体通过手性柱上的 HPLC 分离；9a 和 9b 的外消旋量分别小于 3%。
• Benzoquinolizidine and benzoindolizidine derivatives and therapeutic uses thereof
  申请人：American Biogenetic Sciences, Inc.

  公开号：US06436954B1

  公开（公告）日：2002-08-20

  Benzo[b]quinolizidine and benzo[f]indolizidine derivatives are provided which are useful for the treatment of Alzheimer's disease, senile dementia or other conditions characterized by memory loss. Pharmaceutical compositions containing these compounds, and methods for their use, are also provided.

  本文提供了苯并[b]喹啉和苯并[f]吲哚啉衍生物，这些衍生物可用于治疗阿尔茨海默病、老年性痴呆或其他以记忆丧失为特征的疾病。本文还提供了含有这些化合物的药物组合物以及它们的使用方法。
• PHENANTHROINDOLIZIDINE DERIVATIVE AND NFKB INHIBITOR CONTAINING SAME AS ACTIVE INGREDIENT
  申请人：Ikeda Takashi

  公开号：US20110201637A1

  公开（公告）日：2011-08-18

  A novel compound having an excellent NFκB inhibitory effect is provided. Specifically disclosed is a compound represented by the following formula (1) or a salt thereof: wherein, R 1 represents a hydrogen atom, a lower alkyl group, or the like; R 2 represents a hydrogen atom, a lower alkyl group, a halogen atom, or the like; R 3 represents a hydrogen atom, a lower alkyl group, a hydroxyl group, or a halogen atom; R 4 represents a hydrogen atom or a lower alkyloxy group; R 5 represents a hydrogen atom, a lower alkyloxy group, a halogen atom, a hydroxyl group, or a methylenedioxy group formed together with R 6 or an isopropylidenedioxy group formed together with R 6 ; R 6 represents a hydrogen atom, a lower alkyloxy group, or a methylenedioxy group formed together with R 5 or an isopropylidenedioxy group formed together with R 5 ; R 7 represents a hydrogen atom or a lower alkyl group; and R 8 represents a hydrogen atom, a hydroxyl group, an amino group, a lower alkylcarbonyloxy group, or a halogen atom.

  提供一种具有优异的NFκB抑制效果的新化合物。具体披露的是以下式（1）或其盐的化合物：其中，R1代表氢原子，低碳基或类似物; R2代表氢原子，低碳基，卤素原子或类似物; R3代表氢原子，低碳基，羟基或卤素原子; R4代表氢原子或低碳基氧基; R5代表氢原子，低碳基氧基，卤素原子，羟基或与R6形成的亚甲二氧基或与R6形成的异丙亚甲基二氧基; R6代表氢原子，低碳基氧基或与R5形成的亚甲二氧基或与R5形成的异丙亚甲基二氧基; R7代表氢原子或低碳基; R8代表氢原子，羟基，氨基，低碳基羰基氧基或卤素原子。
• PHENANTHROINDOLIZIDINE COMPOUND AND NFkB INHIBITOR CONTAINING SAME AS ACTIVE INGREDIENT
  申请人：Ikeda Takashi

  公开号：US20110201638A1

  公开（公告）日：2011-08-18

  A novel compound having an excellent NFκB inhibitory effect is provided and specifically disclosed is a compound represented by the following formula (1) or a salt thereof: wherein, R 1 represents a hydrogen atom, a lower alkyl group, a lower alkyloxy group, or a halogen atom; R 2 represents a hydroxyl group, or a lower alkyloxy group; R 3 represents a hydrogen atom, a lower alkyl group, or a halogen atom; R 4 represents a hydrogen atom or a lower alkyloxy group; R 5 represents a hydrogen atom, a lower alkyloxy group, a halogen atom, a hydroxyl group, or a methylenedioxy group formed together with R 6 or an isopropylidenedioxy group formed together with R 6 ; R 6 represents a hydrogen atom, a lower alkyloxy group, or a methylenedioxy group formed together with R 5 or an isopropylidenedioxy group formed together with R 5 ; R 7 represents a hydrogen atom or a lower alkyl group; and R 8 represents a hydrogen atom, a hydroxyl group, an amino group, or a lower alkylcarbonyloxy group (excluding the case where R 1 , R 3 , R 4 and R 7 are hydrogen atoms, R 2 and R 8 are hydroxyl groups, and R 5 and R 6 are methoxy groups).

  提供了一种具有优异NFκB抑制作用的新化合物，具体披露了以下式（1）或其盐的化合物：其中，R1代表氢原子、低级烷基基团、低级烷氧基团或卤素原子；R2代表羟基或低级烷氧基团；R3代表氢原子、低级烷基基团或卤素原子；R4代表氢原子或低级烷氧基团；R5代表氢原子、低级烷氧基团、卤素原子、羟基或与R6形成的亚甲二氧基基团或与R6形成的异丙亚甲二氧基基团；R6代表氢原子、低级烷氧基团或与R5形成的亚甲二氧基基团或与R5形成的异丙亚甲二氧基基团；R7代表氢原子或低级烷基基团；R8代表氢原子、羟基、氨基或低级烷基羧酸酯基团（不包括R1、R3、R4和R7为氢原子，R2和R8为羟基，R5和R6为甲氧基团的情况）。
• M-4 and iso M-4 derivatives, their preparation and compositions containing them
  申请人：SANKYO COMPANY LIMITED

  公开号：EP0065835A1

  公开（公告）日：1982-12-01

  Tetrahydro-M-4 and tetrahydro-IsoM-4 are new compounds which may be prepared by the catalytic hydrogenation of M-4 or IsoM-4 respectively. They, and their salts and esters (which may be prepared by conventional salification or esterification reactions with the parent tetrahydro-M-4 or tetrahydro-IsoM-4), are capable of inhibiting cholesterol biosynthesis in the liver and may be formulated, for therapeutic use, with conventional pharmaceutical carriers or diluents.

  四氢-M-4 和四氢-IsoM-4 是新化合物，可分别通过 M-4 或 IsoM-4 的催化氢化反应制备。它们及其盐类和酯类（可通过与母体四氢-M-4 或四氢-IsoM-4 的常规盐化或酯化反应制备）能够抑制肝脏中胆固醇的生物合成，并可与常规药物载体或稀释剂一起配制成治疗用药。